The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Basit Öğe Kaydı
dc.authorid0000-0001-9584-0827
dc.authorid0000-0002-0443-6966
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorAykan, Musa Barış
dc.contributor.authorMuğlu, Harun
dc.contributor.authorBayram, Ertuğrul
dc.contributor.authorHelvacı, Kaan
dc.contributor.authorDursun, Bengü
dc.contributor.authorCelayir, Melisa
dc.contributor.authorChelebiyev, Elvin
dc.contributor.authorNayır, Erdinç
dc.contributor.authorErman, Mustafa
dc.contributor.authorSezer, Ahmet
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorDemirci, Umut
dc.contributor.authorEr, Özlem
dc.contributor.authorDisel, Umut
dc.contributor.authorBilici, Ahmet
dc.contributor.authorArslan, Çağatay
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2024-09-19T13:08:49Z
dc.date.available2024-09-19T13:08:49Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction: The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi-center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT) in patients with advanced rare tumors. Methods: In this retrospective cohort study, we included 93 patients treated with ICIs for NCI-defined rare tumors from the 12 cancer centers in Turkey. The primary endpoints were the overall response (ORR) and disease control rate (DCR). Results: The cohort's median age was 56, and 53.8% of the patients were male. The most frequent diagnosis was sarcoma (29%), and 81.7% of the patients were previously treated with at least one line of systemic therapy in the advanced stage. The ORR and DCR were 36.8% and 63.2%, respectively. The germ cell tumors had the lowest ORR (0%), while the Merkel cell carcinoma had the highest ORR to ICIs (57.1%). Patients treated with ICI + ICI or ICI plus chemotherapy combinations had higher ORR (55.2% vs. 27.6%, p = 0.012) and DCR (82.8% vs. 53.4%, p = 0.008). The median OS was 13.47 (95% CI: 7.79–19.15) months, and the six and 12-month survival rates were 71% and 52%. The median duration of response was 16.59 months, and the 12-month progression-free survival rate was 66% in responders. The median time-to-treatment failure was 5.06 months (95% CI: 3.42–6.71). Three patients had high-grade irAEs with ICIs (grade 3 colitis, grade 3 gastritis, and grade 3 encephalitis in one patient each). Conclusion: We observed over 30% ORR and a 13-month median OS in patients with rare cancers treated with ICI monotherapy or ICI plus CT combinations. The response rates to ICIs or ICIs plus CT significantly varied across different tumor types. Responding patients had over 2 years of survival, highlighting a need for further trials with ICIs for patients with rare tumors.
dc.identifier.citationGüven, D. C., Aykan, M. B., Muğlu, H., Bayram, E., Helvacı, K., Dursun, B. ... Kılıçkap, S. (2024). The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study. Cancer Medicine, 13(1). http://dx.doi.org/10.1002/cam4.6869
dc.identifier.doi10.1002/cam4.6869
dc.identifier.issn2045-7634
dc.identifier.issue1
dc.identifier.pmid38140782
dc.identifier.scopus2-s2.0-85180694449
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.1002/cam4.6869
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12815
dc.identifier.volume13
dc.identifier.wos001129651900001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMuğlu, Harun
dc.institutionauthorBilici, Ahmet
dc.language.isoen
dc.relation.ispartofCancer Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectImmune Checkpoint Inhibitor
dc.subjectImmunotherapy
dc.subjectRare Tumor
dc.subjectSarcoma
dc.titleThe efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Muğlu-Harun-2024.pdf
Boyut:
617.04 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu